来那度胺治疗的5q缺失骨髓增生异常综合征患者的端粒缩短、克隆进化与疾病进展 - Suppr

Telomere shortening, clonal evolution and disease progression in myelodysplastic syndrome patients with 5q deletion treated with lenalidomide.

作者信息

Göhring G, Lange K, Hofmann W, Nielsen K V, Hellström-Lindberg E, Roy L, Morgan M, Kreipe H, Büsche G, Giagounidis A, Schlegelberger B

出版信息

Leukemia. 2012 Feb;26(2):356-8. doi: 10.1038/leu.2011.193. Epub 2011 Jul 29.

DOI:10.1038/leu.2011.193

PMID:21799512

Abstract

摘要

相似文献

Telomere shortening, clonal evolution and disease progression in myelodysplastic syndrome patients with 5q deletion treated with lenalidomide.

Leukemia. 2012 Feb;26(2):356-8. doi: 10.1038/leu.2011.193. Epub 2011 Jul 29.

Haematological and cytogenetic responses after only 7 days of Lenalidomide in a patient with myelodysplastic syndrome and chromosome 5q deletion.

Leuk Res. 2011 Sep;35(9):e175-6. doi: 10.1016/j.leukres.2011.05.020. Epub 2011 Jun 11.

The difficulty to define progression patterns in patients with early stage myelodysplastic syndromes and deletion 5q--new prognostic markers are needed.

Leuk Res. 2014 Mar;38(3):287-8. doi: 10.1016/j.leukres.2013.12.013. Epub 2013 Dec 26.

A delayed yet durable response to very short lenalidomide therapy and unexpected clone redistribution in a case of myelodysplastic syndrome with del(5q) and del(20q).

Leuk Res. 2009 Nov;33(11):e199-202. doi: 10.1016/j.leukres.2009.06.009. Epub 2009 Jul 9.

Morphologic analysis in myelodysplastic syndromes with del(5q) treated with lenalidomide. A Japanese multiinstitutional study.

Leuk Res. 2012 May;36(5):575-80. doi: 10.1016/j.leukres.2011.11.011. Epub 2011 Dec 15.

Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.

Ann Hematol. 2010 Apr;89(4):365-74. doi: 10.1007/s00277-009-0846-z. Epub 2009 Oct 24.

Long-term transfusion independence in del(5q) MDS patients who discontinue lenalidomide.

Leukemia. 2012 Apr;26(4):855-8. doi: 10.1038/leu.2011.268. Epub 2011 Sep 30.

Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes.

Expert Rev Anticancer Ther. 2010 Oct;10(10):1663-72. doi: 10.1586/era.10.135.

Efficacy of lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2V617F mutation.

Leuk Res. 2011 Sep;35(9):1276-8. doi: 10.1016/j.leukres.2011.06.008. Epub 2011 Jul 20.

Unusual clonal evolution involving 5q in a case of myelodysplastic syndrome with deletion 5q 31 treated with lenalidomide.

Haematologica. 2008 Feb;93(2):315-6. doi: 10.3324/haematol.11917.

引用本文的文献

Influence of Cytogenetics on the Outcome of Patients With High-Risk Myelodysplastic Syndrome Including Deletion 5q Treated With Azacitidine With or Without Lenalidomide.

Genes Chromosomes Cancer. 2025 Feb;64(2):e70029. doi: 10.1002/gcc.70029.

Telomere biology: from disorders to hematological diseases.

Front Oncol. 2023 May 19;13:1167848. doi: 10.3389/fonc.2023.1167848. eCollection 2023.

Short Dysfunctional Telomere Is Highly Predictive of Dismal Outcome in MDS but Not in AML Patients.

Int J Hematol Oncol Stem Cell Res. 2020 Jul 1;14(3):188-199. doi: 10.18502/ijhoscr.v14i3.3728.

Prognostic Markers of Myelodysplastic Syndromes.

Medicina (Kaunas). 2020 Jul 27;56(8):376. doi: 10.3390/medicina56080376.

Routes of Clonal Evolution into Complex Karyotypes in Myelodysplastic Syndrome Patients with 5q Deletion.

Int J Mol Sci. 2018 Oct 21;19(10):3269. doi: 10.3390/ijms19103269.

Dysregulation of Telomere Lengths and Telomerase Activity in Myelodysplastic Syndrome.

Ann Lab Med. 2017 May;37(3):195-203. doi: 10.3343/alm.2017.37.3.195.

Short telomere length and its correlation with gene mutations in myelodysplastic syndrome.

J Hematol Oncol. 2016 Jul 28;9(1):62. doi: 10.1186/s13045-016-0287-9.

Induction of Chromosomal Instability via Telomere Dysfunction and Epigenetic Alterations in Myeloid Neoplasia.

Cancers (Basel). 2013 Jul 4;5(3):857-74. doi: 10.3390/cancers5030857.

Lenalidomide: a review of its use in patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndrome associated with 5q chromosome deletion.

Drugs. 2013 Jul;73(11):1183-96. doi: 10.1007/s40265-013-0071-x.

Efficacy and safety of lenalidomide in patients with myelodysplastic syndrome with chromosome 5q deletion.

Ther Adv Hematol. 2012 Apr;3(2):105-16. doi: 10.1177/2040620711435659.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Telomere shortening, clonal evolution and disease progression in myelodysplastic syndrome patients with 5q deletion treated with lenalidomide.

作者信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献